@article {7705,
	title = {Bortezomib for AL amyloidosis: Moving forward},
	journal = {Blood},
	volume = {118},
	year = {2011},
	note = {Cited By :10Export Date: 21 February 2017},
	month = {2011},
	pages = {827 - 828},
	abstract = {Reece et al report that single-agent bortezomib resulted in hematologic responses in two-thirds of patients with relapsed Light chain (AL) amyloidosis, including complete responses in one-third, while more than 75\% of patients had response duration of more than or equal to 1 year.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-79960969679\&doi=10.1182\%2fblood-2011-05-355115\&partnerID=40\&md5=44b985999349192d148e4d7f40de2c36},
	author = {Dimopoulos, M.A. and Kastritis, E.}
}
